CRISPR Therapeutics AG

CRSP · NASDAQ

A CRISPR Therapeutics five-year double thesis focused on CASGEVY commercialization, cash runway, in-vivo pipeline proof, clinical risk, and dilution discipline.

Follow Add to Watchlist Ask Question

NASDAQ CRSP Biotech Gene Editing High Risk Five-Year Double Thesis

Latest ReportMay 8, 2026CRISPR Therapeutics: CASGEVY launch, pipeline proof, and binary riskView report ->Total Reports2Published reportsView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.